non small cell lung cancer
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
non small cell lung cancer
Jul 26, 2024, 15:10 |
Insight
ASCO's rapid guideline update for the management of stage III NSCLC
American Society of Clinical Oncology (ASCO) shared on LinkedIn: "Just issued: Rapid guideline update for…
Jul 25, 2024, 06:32 |
Insight
Stephen Liu: Novel epigenomic cfDNA approach in diagnosis of EGFR mutant NSCLC
Stephen Liu shared a post on X about a recent paper by Jacob E. Berchuck…
Jul 24, 2024, 08:09 |
Blog
Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination
Gevorg Tamamyan shared on LinkedIn: "As I mentioned in my earlier post, we are ready in…
Jul 18, 2024, 22:37 |
Blog
ESMO Living Guideline on Oncogene-Addicted Metastatic NSCLC
European Society for Medical Oncology (ESMO) shared a post on LinkedIn: ''The new ESMO Living…
Jul 12, 2024, 23:29 |
Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jul 12, 2024, 23:07 |
Insight
Osimertinib could change the standard of care for EGFR-mutant NSCLC
Iván R. González, Medical Oncologist at Ángeles Puebla Hospital, shared on X: "Osimertinib could change…
Jul 8, 2024, 09:42 |
Blog
Gerard Walls: ctDNA, a future tool for radiation therapy personalization in lung cancer?
Gerard Walls, Lung Cancer Clinical Fellow at The Christie NHS Foundation Trust, shared a thread…
Jul 7, 2024, 15:44 |
Blog
Francesco Cortiula: What evidences for the treatment of patients with stage III NSCLC excluded from trials?
Francesco Cortiula, Medical Oncologist at University Hospital of Udine, made the following post on X:…
Jul 6, 2024, 05:13 |
Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jun 29, 2024, 14:04 |
Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 29, 2024, 08:58 |
Insight
Nathan Pennell: EGFR mutation testing, treatment and survival in stage I–III NSCLC
Nathan Pennell, Professor and Vice Chair of Clinical Research at Cleveland Clinic, shared on X: …
Jun 28, 2024, 14:52 |
Insight
Iván R. González: ICIs in early-stage NSCLC showing promising results
Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post…
Jun 28, 2024, 11:08 |
Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 26, 2024, 06:12 |
Insight
Consensus Recommendations from IASLC on neoadjuvant and adjuvant treatment for NSCLC
Rami Manochakian shared a post on X: “Hot off the press! Just published in JTO and…
Jun 26, 2024, 05:25 |
Blog
Aditya Juloori: Greys Anatomy highlights COSINR trial at UChicago Cancer Center
Drew Moghanaki shared a post by Aditya Juloori, radiation oncologist at UChicago Medicine on X: “Wait. What?…
Jun 24, 2024, 12:01 |
Insight
Jean-Charles Soria: Two provocative manuscripts suggest the therapeutic potential of JAK inhibition with immunotherapy in cancer
Jean-Charles Soria shared a post on LinkedIn: "Two provocative manuscripts suggest the therapeutic potential of…
Jun 21, 2024, 13:43 |
Insight
Luca Dezzani: We are requesting approval from the U.S. FDA EGFR-mutated NSCLC therapy
Luca Dezzani, Vice President of US Oncology Medical Affairs at Johnson & Johnson, shared a…
Jun 20, 2024, 01:53 |
Insight
Miguel Bronchud: ESMO recommends performing tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers
Miguel Bronchud, Co-Founder of Regenerative Medicine Solutions, shared on LinkedIn: “2024- ESMO of course recommends…
Jun 19, 2024, 12:33 |
Blog
Maria Babak: How Bevacizumab is revolutionizing treatment for multiple cancers
Maria Babak shared a post by CityU iGEM on LinkedIn: "Discover how Bevacizumab, a powerful cancer…
Jun 18, 2024, 09:36 |
Blog
Drew Moghanaki: Dr. Wen-Zhao Zhong reminding us of the fanfare around drugs and surgery for NSCLC
Drew Moghanaki shared on X: "Dr. Wen-Zhao Zhong presents a slide at ELIXR24 reminding us…
Jun 16, 2024, 17:20 |
Insight
Yvonne Diaz: EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer
Yvonne Diaz, Co-founder of Oncogene Cancer Research, shared a post on X: “Great to see that…
Jun 15, 2024, 05:25 |
Blog
Leora Horn: An update on our recent review published in Trends in Cancer
Leora Horn, Head of Clinical Development, Late Oncology at AstraZeneca, shared a post on LinkedIn: "Together…
Jun 14, 2024, 14:08 |
Blog
Rami Manochakian: Results of PALOMA3 study by Natasha B. Leighl et al
Rami Manochakian shared a post on X: "Hot off the press. Just published in Journal of…
Jun 12, 2024, 07:44 |
Career
Sucheta Guinan: I’m starting a new position as Sr. Director, US HCP Marketing, Oncology at Regeneron!
Sucheta Guinan, Senior Director US HCP Marketing Lead, Oncology at Regeneron, shared on LinkedIn: “I’m…
Jun 10, 2024, 00:53 |
Insight
Vijith Shetty: Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC
Vijith Shetty, Associate Professor and Consultant Medical Oncologist at KS Hegde Medical Academy, shared on…
Jun 3, 2024, 22:53 |
Insight
Paul Healy: AstraZeneca and Daiichi Sankyo have announced positive results from datopotamab deruxtecan in certain lung cancer patients
Paul Healy, Director of PHARMeMED, shared on LinkedIn: "AstraZeneca (AZ) and Daiichi Sankyo have announced positive…
Jun 1, 2024, 15:59 |
Immune Oncology
Immunotherapy for Lung Cancer
Lung cancer and immunotherapy Lung cancer is the leading cause of cancer-related deaths worldwide, with…
Jun 1, 2024, 14:36 |
Blog
Albert Bourla: Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at ASCO24
Albert Bourla, Chairman and Chief Executive Officer of Pfizer, shared a post on LinkedIn: "We’re making…
May 30, 2024, 11:55 |
Blog
Pankaj Kumar Panda: Enriching interactive MTB webinar on First line management of EGFR mutated NSCLC
Pankaj Kumar Panda, Clinical Researcher at National Cancer Centre Singapore, shared a post on X: "Join…
May 27, 2024, 04:19 |
Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
May 25, 2024, 14:28 |
Blog
Studies conducted by Dana-Farber at this year’s AACR Annual Meeting
Dana-Farber Cancer Institute shared on LinkedIn: "Numerous studies conducted by Dana-Farber researchers show promising results for…
May 22, 2024, 08:39 |
Blog
Tanja Obradovic: ASCO just published guidelines for germline genetic testing panels
Tanja Obradovic shared on LinkedIn: "Great service to public and oncology community as ASCO just published…
May 19, 2024, 09:46 |
Blog
June 1 issue of ACS Journal Cancer
ACS Journal Cancer shared a post on X: “Read our June 1 issue! In this issue:…
May 18, 2024, 10:20 |
Insight
Yüksel Ürün: Top Advances of the Year in Perioperative Therapy for Lung Cancer
Yüksel Ürün shared on X: . "Top Advances of the Year: Perioperative Therapy for Lung…
May 12, 2024, 13:31 |
Blog
Stephen Liu: Update from phase 3 IMscin001 trial JTO and JTO CRR
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: “Update from…
May 12, 2024, 07:27 |
Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
May 8, 2024, 00:58 |
Blog
Stephen V Liu: Dr. Passiglia Fra at Rome Lung 24 illustrates the limited role of immunotherapy in driver positive NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University at Lombardi…
May 3, 2024, 22:20 |
Blog
Aren Karapetyan: Latest findings from Ontario revealing dynamic shifts in the management of Stage I NSCLC
Aren Karapetyan, Medical Resident at Yerevan State Medical University named after Mkhitar Heratsi and Secretary at…
May 2, 2024, 23:45 |
Insight
Aakash Desai: Insights into mNSCLC Management through a Global Clinician Survey
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared a post on…
May 2, 2024, 14:30 |
Societies
Glecirasib demonstrates efficacy in KRASG12C-mutated NSCLC - ASCO
American Society of Clinical Oncology (ASCO) shared on X: “Breaking news from the ASCO Plenary Series:…
May 2, 2024, 14:14 |
Blog
Stephen V Liu discusses KRAS mutant NSCLC with Veluswamy and Mariana Brandao - IASLC
International Association for the Study of Lung Cancer (IASLC) shared on X: “KRAS mutations are…
Apr 30, 2024, 06:04 |
Insight
Martin Reck: Update on advanced non oncogenic NSCLC in ASCO Educational Book
Martin Reck, Head of the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, shared…
Apr 29, 2024, 15:02 |
Blog
Patrick Forde: 3 lung cancer plenaries at ASCO24!
Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at…
Apr 28, 2024, 12:40 |
Blog
Cancer at Cedars-Sinai is now recruiting patients with advanced NSCLC in a clinical trial
Cancer at Cedars-Sinai posted on X/Twitter: "If you have advanced non-small cell lung cancer, you…
Apr 28, 2024, 11:04 |
Blog
Ana I. Velázquez Mañana: ASCO24 abstract titles are out! Exciting Plenary Session, specially for LCSM community
Ana I. Velázquez Mañana shared on X/Twitter: “ASCO24 abstract titles are out! Exciting Plenary Session, specially…
Apr 27, 2024, 08:27 |
Societies
American Radium Society Appropriate Use Criteria Thoracic Committee provided guidance on the management of unresectable locally advanced NSCLC - MSK Radiation Oncology
Memorial Sloan Kettering Radiation Oncology shared on X: “Evidence-based guidance on the management of unresectable…
Apr 26, 2024, 10:07 |
Drugs
Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer
Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter: ''HOT OFF…
Apr 26, 2024, 10:00 |
Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 26, 2024, 09:26 |
Insight
Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: ''First-line treatment…
Apr 23, 2024, 18:57 |
Insight
New Paper Alert! Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of the Literature
Identifying a New EGFR Germline Mutation in Lung Adenocarcinoma: A Case Report and Review of…
Apr 23, 2024, 10:44 |
Blog
Ben Solomon: A timely discussion with Narjust Florez about the ALINA trial
Ben Solomon, Lung Cancer Medical Oncologist at Peter MacCallum Cancer Centre, shared a post by…
Apr 22, 2024, 18:48 |
Insight
Piotr Wysocki: Single-agent immunotherapy is a wise choice as first-line treatment in elderly, advanced NSCLC patients, irrespectively of PD-L1 expression
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 21, 2024, 18:13 |
Blog
Antonio Passaro: An intense yet incredibly rewarding day in Oporto
Antonio Passaro, Medical Director with Highly Specialized Position at IEO European Institute of Oncology, shared a…
Apr 21, 2024, 11:35 |
Insight
Samuel Kareff: Our pan-tumor analysis on the not-so-elusive HRAS mutation in solid tumors
Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, shared…
Apr 20, 2024, 06:08 |
Insight
David Planchard: Some advances for our BRAF V600E NSCLC patients…Review to read at npj Journals
David Planchard, Professor at the University of Paris-Saclay, posted on X/Twitter: "Some advances for our BRAF…
Apr 19, 2024, 15:52 |
Drugs
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial
FDA, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following…
Apr 17, 2024, 17:25 |
Insight
Susanna Greer: A 'not-so-small' discovery for non-small cell lung cancer
Susanna Greer, Chief Scientific Officer at the V Foundation for Cancer Research, published the following…
Apr 15, 2024, 13:28 |
Insight
Antonio Passaro: Release of our editorial, co-authored with Peters Solange, focusing on the groundbreaking ALINA study
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared on LinkedIn: ''I am thrilled…
Apr 14, 2024, 07:35 |
Drugs
Charles Swanton: What is the role of the TME in lung cancer evolution?
Charles Swanton, Professor at University College London Cancer Institute, shared on X/Twitter: "What is the role…
Apr 14, 2024, 02:26 |
Insight
Vivek Subbiah: A pan-cancer analysis of the microbiome in metastatic cancer
Quoting Vivek Subbiah on X/Twitter: "A pan-cancer analysis of the microbiome in metastatic cancer: Cell.…
Apr 13, 2024, 12:35 |
Opinion
Stephen V Liu: Some guidance on the management of adverse events with sotorasib in KRAS G12C NSCLC Lung Cancer Journal
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared a post…
Apr 13, 2024, 09:40 |
Drugs
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X: "Hot off…
Apr 12, 2024, 11:46 |
Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
Apr 11, 2024, 17:15 |
Blog
Oyepeju Abioye: 'Precision Immuno-Oncology in NSCLC through Gender Equity Lenses', published in MDPI
Oyepeju Abioye, Oncology Clinical Research Assistant at Florez Laboratory of Dana-Farber Cancer Institute, shared on X:…
Apr 9, 2024, 09:03 |
Insight
Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Apr 8, 2024, 23:10 |
Blog
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "Our collaborative effort…
Apr 8, 2024, 22:24 |
Insight
NSCLC's Immune Landscape: A Comprehensive Study of the Tumor Microenvironment
A recent study, “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical…
Apr 8, 2024, 16:54 |
Blog
Antonio Passaro: The phase 3 KRYSTAL-12 trial represents a significant advancement in our understanding and treatment of KRAS-mutated NSCLC
Antonio Passaro, Medical Oncologist at European Institute of Oncology, shared a post on LinkedIn: "Why…
Apr 8, 2024, 16:47 |
Insight
Nathan Pennell: First published article in the 2024 ASCO Educational Book
Mariam Mailyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post by Nathan Pennel,…
Apr 4, 2024, 13:34 |
Drugs
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "NSCLC and anti-EGFR treatments…
Apr 3, 2024, 15:42 |
Drugs
Jarushka Naidoo: Phase II trial of Tumor-Infiltrating Lymphocyte (TIL) therapy (Lifileucel) in Advanced Non-Small Cell Lung Cancer post Immunotherapy with or without chemotherapy
Mar 29, 2024, 18:40 |
Insight
Jarushka Naidoo: Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+ NSCLC meets primary PFS endpoint
Jarushka Naidoo shared on X/Twitter: "Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+…
Mar 25, 2024, 15:21 |
Insight
Gerry Hanna: Breaking from ELCC - PACIFIC-2 is negative
Gerry Hanna, Chair of the Division of Cancer and Specialist Medicine at Belfast Health and…
Mar 11, 2024, 18:00 |
Societies
Florez Lab: A fantastic discussion on Nivolumab and Non-Small Cell Lung Cancer
Florez Lab posted on X/Twitter: "What podcast should you listen to today? In this episode…
Mar 6, 2024, 11:34 |
Drugs
Rami Manochakian: U.S. FDA approves Amivantamab WITH CHEMOTHERAPY for 1st Line treatment of advanced non-small cell Lung Cancer with EGFR
Rami Manochakian, Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: “HOT OFF THE PRESS…
Mar 1, 2024, 03:00 |
Blog
A survey of U.S. oncologists on the use of innovative treatments - Cancer Research Institute
Cancer Research Institute shared a post on LinkedIn: "Advancements in the research and treatment of advanced…
Feb 24, 2024, 16:34 |
Blog
Chul Kim: What are other relevant targets for ADC therapy in NSCLC?
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: "What are…
Feb 17, 2024, 15:57 |
Insight
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter: "Hot off…
Feb 7, 2024, 12:46 |
Blog
Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC
Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…
Jan 13, 2024, 10:04 |
Blog
Nathan A. Pennell: Pralsetinib development outside the US and China also stopped
Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by…
Jan 11, 2024, 18:00 |
Blog
Aruni Ghose: Beginning 2024 with this masterpiece in the Lung Cancer Landscape
Aruni Ghose, Focused Topic Network Member at European Cancer Organisation, shared a post on LinkedIn: "Beginning…
Jan 8, 2024, 14:21 |
Blog
Drew Moghanaki shared a study from Duke University on Stage I NSCLC
Drew Moghanaki, Lung Cancer Specialist at UCLA Health Jonsson Cancer Center, shared a post on…
Nov 28, 2023, 18:00 |
Drugs
Stephen V Liu: Report on real world efficacy and safety of amivantamab including off label use
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at the Lombardi Comprehensive Cancer…
Oct 13, 2023, 17:10 |
Drugs
Rami Manochakian: FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.
Oct 6, 2023, 16:28 |
Blog
Happy birthday BioRadon! - European Organisation for Research and Treatment of Cancer (EORTC)
Quoting European Organisation for Research and Treatment of Cancer (EORTC) on LinkedIn: “Happy birthday BioRadon!…
All:
85
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube